| Revenue growth | 31.2% YoY |
|---|---|
| Margins | EBITDA margin compressed to 3.7% from 7.9% YoY. |
| Demand visibility | Early signs of improvement despite Middle East logistics challenges. |
Growth
Revenue grew 31.2% YoY but declined 10.5% QoQ. PAT fell to a loss of ₹40 Mn vs ₹19 Mn loss YoY.
Outlook
Focus on EU/UK NIP/OTF pipeline with 3 approvals secured; CAPA remediation for EU-GMP is largely complete and implemented.
Risks
War in Mid East and logistics challenges impacted QoQ performance. Higher utility and employee costs compressed margins.
Last quarter's promises, checked
Delivered
- CAPA implementation → Substantially completed and implemented (= BEAT)
- EU GMP re-inspection → Conducted May 4-7, 2026 (= BEAT)
- NIP+OTF revenue growth → Tripled YoY to ₹138 Mn (= BEAT)
Partly delivered
- Middle East recovery → Nutra grew 71% YoY but logistics/war risks persist (= PARTIAL)
Missed
- EBITDA margin → Compressed to 3.7% from 12.7% in Q4 (= MISS)
- Revenue trajectory → Declined 10.5% QoQ (= MISS)
- Finance costs → Guided constant but rose 10.3% (= MISS)
Investor Presentation filed with NSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹138.48
- Market cap
- ₹743.1 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 201.0×Sector 50.4×
- Promoter holding
- 30.36%+0.01% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
- Value
- ₹2.38 Cr
Zim Laboratories Investor Presentation: Key Takeaways
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
- Call
- Guides 32% growth
Zim Laboratories Q1 FY27 Results: Net Loss of ₹4 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.
- Key figure
- Net loss ₹4 Cr